TITLE

The Rationale and Future Potential of Angiogenesis Inhibitors in Neoplasia

AUTHOR(S)
Gasparini, Giampietro
PUB. DATE
July 1999
SOURCE
Drugs;Jul1999, Vol. 58 Issue 1, p17
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Malignant tumours are angiogenesis-dependent diseases. Several experimental studies suggest that primary tumour growth, invasiveness and metastasis require neovascularisation. Tumour-associated angiogenesis is a complex multistep process under the control of positive and negative soluble factors. A mutual stimulation occurs between tumour and endothelial cells by paracrine mechanisms. Angiogenesis is necessary, but not sufficient, as the single event for tumour growth. There is, however, compelling evidence that acquisition of the angiogenic phenotype is a common pathway for tumour progression, and that active angiogenesis is associated with other molecular mechanisms leading to tumour progression. Experimental research suggests that it is possible to block angiogenesis by specific inhibitory agents, and that modulation of angiogenic activity is associated with tumour regression in animals with different types of neoplasia. The more promising angiosuppressive agents for clinical testing are: naturally occurring inhibitors of angiogenesis (angiostatin, endostatin, platelet factor-4 and others), specific inhibitors of endothelial cell growth (TNP-470, thalidomide, interleukin-12 and others), agents neutralising angiogenic peptides (antibodies to fibroblast growth factor or vascular endothelial growth factor, suramin and analogues, tecogalan and others) or their receptors, agents that interfere with vascular basement membrane and extracellular matrix [metalloprotease (MMP) inhibitors, angiostatic steroids and others], antiadhesion molecules antibodies such as anti-integrin avb3, and miscellaneous drugs that modulate angiogenesis by diverse mechanisms of action. Antiangiogenic therapy is to be distinguished from vascular targeting. Gene therapy aimed to block neovascularisation is also a feasible anticancer strategy in animals bearing experimental tumours. Antiangiogenic therapy represents one of the more promising new approaches to anticancer therapy and it is...
ACCESSION #
9523845

 

Related Articles

  • Endogenous inhibitors of angiogenesis in malignant gliomas: Nature's antiangiogenic therapy. Rege, Tanya A.; Fears, Constance Y.; Gladson, Candece L. // Neuro-Oncology;Apr2005, Vol. 7 Issue 2, p106 

    Angiogenesis is necessary for tumor growth beyond a volume of approximately 2 mm². This observation, along with the accessibility of tumor vessels to therapeutic targeting, has resulted in a research focus on inhibitors of angiogenesis. A number of endogenous inhibitors of angiogenesis are...

  • PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Dredge, K.; Hammond, E.; Handley, P.; Gonda, T. J.; Smith, M. T.; Vincent, C.; Brandt, R.; Ferro, V.; Bytheway, I. // British Journal of Cancer;2/15/2011, Vol. 104 Issue 4, p635 

    Background:PG545 is a heparan sulfate (HS) mimetic that inhibits tumour angiogenesis by sequestering angiogenic growth factors in the extracellular matrix (ECM), thus limiting subsequent binding to receptors. Importantly, PG545 also inhibits heparanase, the only endoglycosidase which cleaves HS...

  • Anti-angiogenic therapy increases intratumoral adenovirus distribution by inducing collagen degradation. Thaci, B; Ulasov, I V; Ahmed, A U; Ferguson, S D; Han, Y; Lesniak, M S // Gene Therapy;Mar2013, Vol. 20 Issue 3, p318 

    Conditionally replicating adenoviruses (CRAd) are a promising class of gene therapy agents that can overcome already known glioblastoma (GBM) resistance mechanisms but have limited distribution upon direct intratumoral (i.t.) injection. Collagen bundles in the extracellular matrix (ECM) have an...

  • Anti-angiogenesis: making the tumor vulnerable to the immune system. Griffioen, Arjan W. // Cancer Immunology, Immunotherapy;Oct2008, Vol. 57 Issue 10, p1553 

    Ongoing angiogenesis has been shown to possess immune suppressive activity through several mechanisms. One of these mechanisms is the suppression of adhesion receptors, such as intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and E-selectin—adhesion molecules involved...

  • Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivo. Jin, Xiaomei; Bookstein, Rob; Wills, Ken; Avanzini, Jenny; Tsai, Van; LaFace, Drake; Terracina, Gaby; Shi, Bin; Nielsen, Loretta L // Cancer Gene Therapy;Dec2001, Vol. 8 Issue 12, p982 

    Progressive growth and metastasis of solid tumors require angiogenesis, or the formation of new blood vessels. Endostatin is a 20-kDa carboxy-terminal fragment of collagen XVIII that has been shown to inhibit endothelial cell proliferation and tumor angiogenesis. Replication-deficient...

  • Rola metaloproteinaz w modyfikacji macierzy zewnÄ…trzkomórkowej w nowotworowym wzroÅ›cie inwazyjnym, w przerzutowaniu i w angiogenezie. Fink, Krzysztof; Boratyński, Janusz // Advances in Hygiene & Experimental Medicine / Postepy Higieny i ;2012, Vol. 66, p609 

    Extracellular matrix metalloproteinases (MMPs) are a family of endopeptydases which recquire a zinc ion at their active site, for proteolityc activity. There are six members of the MMP family: matrilysins, collagenases, stromelysins, gelatinases, membrane MMPs and other MMPs. Activity of MMPs is...

  • Adenovirus-mediated delivery of antiangiogenic genes as an antitumor approach. Régulier, Etienne; Paul, Stéphane; Marigliano, Martine; Kintz, Jacqueline; Poitevin, Yves; Ledoux, Catherine; Roecklin, Dominique; Cauet, Gilles; Calenda, Valérie; E. Homann, Horst // Cancer Gene Therapy;Jan2001, Vol. 8 Issue 1, p45 

    Based on the observation that the growth of solid tumors is dependent on the formation of new blood vessels, therapeutic strategies aimed at inhibiting angiogenesis have been proposed. A number of proteins with angiostatic activity have been described, but their development as therapeutic agents...

  • Inhibitors of angiogenesis selectively reduce the malignant cell load in rodent models of human myeloid leukemias. Iversen, P.O.; Sorensen, D.R.; Benestad, H.B. // Leukemia (08876924);Mar2002, Vol. 16 Issue 3, p376 

    Angiogenesis is essential for growth and metastasis of solid tumors and probably also for hematological malignancies. Angiogenic inhibitors, like endostatin (ES) and PI-88, retard cancer growth. We tested these in mice with juvenile myelomonocytic leukemia (JMML), and in rats with acute myeloid...

  • Angiogenesis: Basement membranes: structure, assembly and role in tumour angiogenesis. Kalluri, Raghu // Nature Reviews Cancer;Jun2003, Vol. 3 Issue 6, p422 

    In recent years, the basement membrane (BM) -- a specialized form of extracellular matrix (ECM) -- has been recognized as an important regulator of cell behaviour, rather than just a structural feature of tissues. The BM mediates tissue compartmentalization and sends signals to epithelial cells...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics